

Glavna skupština Društva Teva Pharmaceutical Industries Ltd.

Dana 13. srpnja 2017. godine održati će se Glavna skupština Društva **Teva Pharmaceutical Industries Ltd.** čije dionice u svojem portfelju imaju fondovi AZ obvezni mirovinski fond kategorije A i AZ obvezni mirovinski fond kategorije B.

Društvo će za račun gore navedenih fondova glasovati po pojedinim točkama dnevnog reda kako slijedi:

Točke dnevnog reda		Odluke
1.	To appoint the following persons to the Board of Directors, each to serve until our 2020 annual meeting of shareholders:	
1a.	Dr. Sol J.Barer	ZA/FOR
1b.	Mr. Jean-Michel Halfon	ZA/FOR
1c.	Mr. Murray A. Goldberg	ZA/FOR
1d.	Mr. Nechemia (Chemi) J. Peres	ZA/FOR
	and to appoint the following persons to the Board of Directors, each to serve until our 2019 annual meeting of shareholders:	
1e.	Mr. Roberto Mignone	ZA/FOR
1f.	Dr. Perry D. Nisen	ZA/FOR
2.	To approve the compensation of Dr. Sol J. Barer as Chairman of the Board of Directors	ZA/FOR
3.	To approve the terms of office and employment of Dr. Yitzhak Peterburg as Interim President and Chief Executive Officer	ZA/FOR
4.	To approve a membership fee for directors serving on special or ad-hoc committees	ZA/FOR
5.	To approve an amendment to the 2015 Long-Term Equity-Based Incentive Plan to increase the number of shares available for issuance thereunder	ZA/FOR
6.	To approve Teva's 2017 Executive Incentive Compensation Plan	ZA/FOR
7.	To reduce Teva's registered share capital to NIS 249,434,338, by canceling 424,247 Ordinary "A" Shares, par value NIS 0.1 per share and 5,232,377 ordinary shares, par value NIS 0.1 per share and to make corresponding amendments to Teva's Memorandum of Association and Articles of Association	ZA/FOR
8.	To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2018 annual meeting of shareholders	ZA/FOR